Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts. Show more

Location: 80 Guest Street, Boston, MA, 02135, United States | Website: https://www.compasstherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

373.4M

52 Wk Range

$0.87 - $4.08

Previous Close

$2.85

Open

$2.82

Volume

1,009,555

Day Range

$2.64 - $2.84

Enterprise Value

253.3M

Cash

112.6M

Avg Qtr Burn

-11.04M

Insider Ownership

14.16%

Institutional Own.

70.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2/3

Data readout

CTX-471 +/- KEYTRUDA® (pembrolizumab) Details
Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma

Phase 2

Initiation

Phase 2

Initiation

CTX-8371 Details
Cancer, Solid tumor/s

Phase 1

Data readout

IND

Submission